Curanex Pharmaceuticals Inc. (CURX), a pharmaceutical development company, on Thursday announced first quarter results and highlighted progress of its lead drug candidate Phyto-N, which is being advanced towards a planned FDA submission for ulcerative colitis.
Q1 2026:
Curanex reported cash and cash equivalents on March 31, 2026, amounting to $4 million. The company estimated that the available capital will be sufficient to support key upcoming development activities for its lead drug candidate Phyto-N.
Pipeline Highlights:
Phyto-N is being evaluated as a potential treatment of ulcerative colitis in studies to determine toxicology and pharmacokinetics of the drug.
A preclinical toxicology, dose-finding trial was completed in March, with Phyto-N administered as a 28-day repeated dose in dogs and rats. No adverse effects were reported at multiple dose levels.
The company plans to advance the investigational new drug (IND) submission for Phyto-N to the FDA by the fourth quarter of this year.
Curanex also plans to initiate studies exploring treatments for cancer cachexia, which currently has no FDA-approved therapies.
The company noted that the global cancer cachexia market was valued at $2.54 billion in 2024 and is projected to reach approximately $3.90 billion by 2033, underscoring the unmet need.
CYRX is currently trading at $0.31, up 0.67%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.